论文部分内容阅读
据德国医药年报《Arzneiverordnungs——Report 1997》报道,德国特种高价药品销势强劲,1996年该类22个药品总销售额达15亿德国马克(合8.30亿美元,增长230％),超过当年上市新药的总销售额。 德国1996年免疫抑制剂销售额增长5.45亿德国马克,其中山地明(ciclosporin,Sandimmun)、Prograf(taerolimus)和干扰素α-2b(interferon α-2b,Intron A)发展势头特别强劲,抗贫血药Erypo(epoetin α)和Recormon(epoetin β)同样市道畅通。
According to the German medical annual report “Arzneiverordnungs - Report 1997”, the sales of special high-priced medicines in Germany were strong. In 1996, the sales volume of such 22 medicines reached DMr1.5 billion (about 830 million U.S. dollars, up 230%), surpassing that of the new drug Of total sales. German 1996 immunosuppressant sales increased 545 million German marks, of which ciclosporin (Sandimmun), Prograf (taerolimus) and interferon α-2b (Intron A) are particularly strong momentum of development, anti-anemia drugs Erypo (epoetin α) and Recormon (epoetin β) the same market flow.